Lowell T. Harmison
Directeur Général chez ProCell Corp.
Profil
Lowell T.
Harmison has been a Director of Signalife, Inc. since June 6, 2003 and Chairman of the World Doc Foundation since June 2002.
He has been a Director and Chief Executive Officer of ProCell Corp.
since June 2000 and a Director of pHA Bio Remediation since 1997.
Dr. Harmison was Interim Chief Executive Officer of Signalife from March 26, 2005 to April 15, 2005 and Co-Chief Executive Officer from April 15, 2005 to July 15, 2005.
He has been a Senior Advisor since February 2003.
Dr. Harmison has 35 years of experience in the field of biomedicine.
He was Chairman of the Sequella Foundation and a Director of Sequella, Inc. from 1997 to 2000.
Dr. Harmison was Chief Executive Officer of USET, Inc. from 1987 to 1989 and Chief Operating Executive of the Maxwell Foundation.
He was Director of the Robert Maxwell Foundation from 1987 to 1989.
He served as Principal Deputy Assistant Secretary for Health of the US Public Health Service, Department of Health and Human Services.
Dr. Harmison was Founder, a Director and Chairman of the Sequella Global TB Foundation.
He received a PhD from the University of Maryland and a BS, an MS and an Honorary Doctor of Science degree from West Virginia University.
Postes actifs de Lowell T. Harmison
| Sociétés | Poste | Début |
|---|---|---|
| World Doc Foundation | Président | 01/06/2002 |
| pHA Bio Remediation | Directeur/Membre du Conseil | 01/01/1997 |
| ProCell Corp. | Directeur Général | 01/06/2000 |
Anciens postes connus de Lowell T. Harmison
| Sociétés | Poste | Fin |
|---|---|---|
Signalife, Inc.
 Signalife, Inc. Medical SpecialtiesHealth Technology The Group's principal activity is to develop, research and market heart monitors and other diagnostic medical devices. The Group's product Model 100 ambulatory monitor system which monitor, which collects, processes and records data, as well as will enable physicians to monitor the changes in the patient's physiological signals and assist in the detection of heart disease through the conduct of electrocardiogram tests. The Group is a development stage company. | President | - |
Expériences
Fonctions occupées
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Signalife, Inc.
Signalife, Inc. Medical SpecialtiesHealth Technology The Group's principal activity is to develop, research and market heart monitors and other diagnostic medical devices. The Group's product Model 100 ambulatory monitor system which monitor, which collects, processes and records data, as well as will enable physicians to monitor the changes in the patient's physiological signals and assist in the detection of heart disease through the conduct of electrocardiogram tests. The Group is a development stage company. | Health Technology |
| World Doc Foundation | |
| pHA Bio Remediation | |
| ProCell Corp. |